[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100550306":3},{"organization":4,"armGroups":7,"interventions":13,"overallOfficials":19,"centralContacts":20,"locations":27,"responsibleParty":44,"collaborators":19,"id":46,"slug":47,"hasResults":48,"nctId":49,"briefTitle":50,"officialTitle":51,"acronym":52,"eligibilityCriteria":53,"healthyVolunteers":48,"sex":54,"minAge":55,"maxAge":19,"enrollmentInfo":56,"targetDuration":19,"studyType":59,"phases":60,"briefSummary":62,"conditions":63,"keywords":19,"overallStatus":29,"whyStopped":19,"lastUpdateSubmitDate":67,"lastUpdatePostDateStruct":68,"startDateStruct":71,"completionDateStruct":73,"leadSponsor":75,"locationsCount":76},{"fullName":5,"class":6},"Ziekenhuis Oost-Limburg","OTHER",[8],{"label":9,"type":6,"description":10,"interventionNames":11},"Study cohort","FibroScan measurement",[12],"Diagnostic Test: FibroScan",[14],{"type":15,"name":16,"description":17,"armGroupLabels":18,"otherNames":19},"DIAGNOSTIC_TEST","FibroScan","Performance of a FibroScan measurement to determine steatosis and fibrosis.",[9],null,[21],{"name":22,"role":23,"phone":24,"phoneExt":25,"email":26},"Leen Heyens, MsC","CONTACT","089 21 20 55","+32","nafldstudie@zol.be",[28],{"facility":5,"status":29,"city":30,"state":31,"zip":32,"country":33,"countryCode":34,"cosmosGeoPoint":35,"geoPoint":40,"contacts":41},"RECRUITING","Genk","Limburg","3600","Belgium","BE",{"type":36,"coordinates":37},"Point",[38,39],5.50082,50.965,{"lat":39,"lon":38},[42],{"name":22,"role":23,"phone":24,"phoneExt":25,"email":43},"NAFLDstudie@zol.be",{"type":45,"investigatorFullName":19,"investigatorTitle":19,"investigatorAffiliation":19,"oldNameTitle":19,"oldOrganization":19},"SPONSOR","100550306","prevalence-of-nafld-in-t1dm-patients-100550306",false,"NCT06445361","Prevalence of NAFLD in T1DM Patients","The Prevalence of Non-Alcoholic Fatty Liver Disease in Type 1 Diabetes Mellitus Patients Followed at Ziekenhuis Oost-Limburg, Genk, Belgium","PAD1ZOL","Inclusion Criteria:\n\n* T1DM\n* ≥ 18 years of age\n* Written informed consent obtained\n\nExclusion Criteria:\n\n* Excessive alcohol use\n* Exclusion of other causes of liver disease and secondary causes of liver steatosis","ALL","18 Years",{"count":57,"type":58},138,"ESTIMATED","INTERVENTIONAL",[61],"NA","To determine the prevalence of NAFLD in T1DM patients.",[64,65,66],"NAFLD","Type 1 Diabetes","Fatty Liver, Nonalcoholic","2025-07-22",{"date":69,"type":70},"2025-07-28","ACTUAL",{"date":72,"type":70},"2023-07-01",{"date":74,"type":58},"2026-07-01",{"name":5,"class":6},1]